What Is DB-1310?
DB-1310 is a type of medicine known as an antibody-drug conjugate (ADC). It works by attaching a powerful chemotherapy drug to an antibody that specifically recognizes HER3, a protein often found on cancer cells. This allows the treatment to deliver cancer-killing medicine directly to tumor cells, while helping to spare healthy cells and reduce side effects.
Who Was Studied?
- The ongoing phase 1/2a international clinical trial includes 172 patients with advanced solid tumors that did not respond to standard treatments.
- Many of these patients had non-small cell lung cancer (NSCLC) with mutations in the EGFR gene, a group that often runs out of effective treatment options.
- Some patients also had cancer that had spread to the brain.
What Are the Results So Far?
- In patients with EGFR-mutant NSCLC,
- 44% saw their tumors shrink with DB-1310.
- The drug kept cancer from growing for a median of 7 months.
- Median overall survival was 18.9 months.
- Across all patients in the study,
- 31% responded to treatment (tumor shrinkage).
- The average time before cancer started growing again was 5.5 months.
- Median overall survival was 14.4 months.
- Side effects were generally manageable, with the most common being low blood counts and nausea.
These results are especially encouraging for people with advanced cancers who have already tried many other treatments. The study is still ongoing, and more patients are being enrolled. Larger studies are needed to confirm these early results.
If you or a loved one has advanced cancer that has stopped responding to treatment, ask your doctor about clinical trials and whether new options like DB-1310 may be available in the future.
Reference
Lisberg A, Lu S, Hamilton EP, et al. DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1/2a trial. Presented at the 2025 American Society of Clinical Oncology Annual Meeting. May 30-June 3, 2025. Chicago, IL. Abstract 3000.
